All Stories

  1. Bone Density, Microarchitecture, and Geometry Assessment in Patients with Pachydermoperiostosis Using Second-Generation High-Resolution Peripheral Quantitative Computed Tomography: A Case–Control Study
  2. A Novel De Novo Nonsense Pathogenic Variant in IGSF1 Resulting in Central Hypothyroidism and Transient GH Deficiency
  3. RET signalling in the pituitary: a double-edged sword for differentiation, apoptosis and therapeutic strategies in acromegaly
  4. Clinical features of acromegaly
  5. Bone mineral density, turnover, and microarchitecture assessed by second-generation high-resolution peripheral quantitative computed tomography in patients with Sheehan’s syndrome
  6. Tall stature and gigantism in adult patients with acromegaly
  7. Consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence: Part 2, specific diseases
  8. Consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence: Part 1, general recommendations
  9. Multiple Endocrine Neoplasia and Familial Isolated Pituitary Adenoma in the Paediatric Population
  10. Genetic Testing in Hereditary Pituitary Tumors
  11. Pharmacological and Genetic Disruption of C-Type Natriuretic Peptide (nppcl) Expression in Zebrafish (Danio rerio) Causes Stunted Growth during Development
  12. Live Fast, Die Young?
  13. Effective Long-term Pediatric Pegvisomant Monotherapy to Final Height in X-linked Acrogigantism
  14. Tumour microenvironment and pituitary tumour behaviour
  15. Insulinomatosis: new aspects
  16. Evaluating home injection compared with healthcare-setting injection of somatostatin analogs: a systematic literature review
  17. Succinate dehydrogenase and MYC-associated factor X mutations in pituitary neuroendocrine tumours
  18. AIP: A double agent? The tissue-specific role of AIP as a tumour suppressor or as an oncogene
  19. Ockham’s Razor for a Retinal Lesion and Acromegaly and Breaking the Vicious Circle
  20. Glucose and lipid metabolism abnormalities in Cushing’s syndrome
  21. Long-term Safety of Growth Hormone in Adults With Growth Hormone Deficiency: Overview of 15 809 GH-Treated Patients
  22. Temozolomide Nonresponsiveness in Aggressive Prolactinomas and Carcinomas: Management and Outcomes
  23. Approach to the Patient With Pseudoacromegaly
  24. Sex-biased islet β cell dysfunction is caused by the MODY MAFA S64F variant by inducing premature aging and senescence in males
  25. Serum Inflammation-based Scores in Endocrine Tumors
  26. Genetics of Acromegaly and Gigantism
  27. Molecular characterization of DICER1-mutated pituitary blastoma
  28. The clinical aspects of pituitary tumour genetics
  29. Patients with rare endocrine conditions have corresponding views on unmet needs in clinical research
  30. Pre-operative serum inflammation-based scores in patients with pituitary adenomas
  31. Update on the Genetics of Pituitary Tumors
  32. The tumour microenvironment of pituitary neuroendocrine tumours
  33. Unusual Combination of MEN-1 and the Contiguous Gene Deletion Syndrome of CAH and Ehlers-Danlos Syndrome (CAH-X)
  34. XAF1 as a modifier of p53 function and cancer susceptibility
  35. Phenotypic and genotypic features of a large kindred with a germline AIP variant
  36. Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial
  37. Novel Insights into Pituitary Tumorigenesis: Genetic and Epigenetic Mechanisms
  38. Significant Benefits of AIP Testing and Clinical Screening in Familial Isolated and Young-onset Pituitary Tumors
  39. Pachydermoperiostosis mimicking the acral abnormalities of acromegaly
  40. Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours
  41. Pituitary tumour fibroblast-derived cytokines influence tumour aggressiveness
  42. Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours
  43. Redefining the perioperative stress response: a narrative review
  44. Plasma Renin Measurements are Unrelated to Mineralocorticoid Replacement Dose in Patients With Primary Adrenal Insufficiency
  45. Pediatric Parathyroid Carcinoma: A Case Report and Review of the Literature
  46. Surgery, Octreotide, Temozolomide, Bevacizumab, Radiotherapy, and Pegvisomant Treatment of an AIP Mutation‒Positive Child
  47. Acromegaly associated with GIST, non-small cell lung carcinoma, clear cell renal carcinoma, multiple myeloma, medulla oblongata tumour, adrenal adenoma, and follicular thyroid nodules
  48. Aryl Hydrocarbon Receptor Interacting Protein Maintains Germinal Center B Cells through Suppression of BCL6 Degradation
  49. Circulating aryl hydrocarbon receptor-interacting protein (AIP) is independent of GH secretion
  50. Phosphodiesterases and cAMP Pathway in Pituitary Diseases
  51. Tumor microenvironment defines the invasive phenotype of AIP-mutation-positive pituitary tumors
  52. Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study
  53. Germline and mosaic mutations causing pituitary tumours: genetic and molecular aspects
  54. The current landscape of European registries for rare endocrine conditions
  55. Assessment of Cardiavascular Changes following Trans-sphenoidal Surgery in Acromegalic Patients
  56. Genetics of Pituitary Tumours
  57. Proteomic Analysis of the Human Anterior Pituitary Gland
  58. Pseudoacromegaly
  59. Reduced protein expression of the phosphodiesterases PDE4A4 and PDE4A8 in AIP mutation positive somatotroph adenomas
  60. Pituitary Pathology and Gene Expression in Acromegalic Cats
  61. Coexisting pituitary and non-pituitary gigantism in the same family
  62. International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature
  63. Giant Prolactinoma of Young Onset: A Clue to Diagnosis of MEN-1 Syndrome
  64. Clinical and Pathological Aspects of Silent Pituitary Adenomas
  65. Survivin as a potential therapeutic target of acetylsalicylic acid in pituitary adenomas
  66. Macimorelin as a Diagnostic Test for Adult GH Deficiency
  67. A novel DICER1 mutation in familial multinodular goitre
  68. UPDATE ON THE CLINICOPATHOLOGY OF PITUITARY ADENOMAS
  69. Prophylactic thyroidectomy in children with multiple endocrine neoplasia type 2
  70. In vivo bioassay to test the pathogenicity of missense human AIP variants
  71. De novo HNF1 homeobox B mutation as a cause for chronic, treatment-resistant hypomagnesaemia
  72. Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target
  73. Risk category system to identify pituitary adenoma patients with AIP mutations
  74. MAFA missense mutation causes familial insulinomatosis and diabetes mellitus
  75. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016
  76. Cantú syndrome with coexisting familial pituitary adenoma
  77. Multi-chaperone function modulation and association with cytoskeletal proteins are key features of the function of AIP in the pituitary gland
  78. Emergence of Pituitary Adenoma in a Child during Surveillance: Clinical Challenges and the Family Members’ View in anAIPMutation-Positive Family
  79. Metabolic Syndrome in Cushing's Syndrome Patients
  80. Preliminaries
  81. AIP mutations in Brazilian patients with sporadic pituitary adenomas: a single-center evaluation
  82. Somatic USP8 mutations are frequent events in corticotroph tumor progression causing Nelson’s tumor
  83. AIP and the somatostatin system in pituitary tumours
  84. Mechanical, hormonal and metabolic influences on blood vessels, blood flow and bone
  85. Fatal Carney Complex in Siblings Due to De Novo Large Gene Deletion
  86. Pseudoacromegaly: A Differential Diagnostic Problem for Acromegaly With a Genetic Solution
  87. In-frame seven amino-acid duplication in AIP arose over the last 3000 years, disrupts protein interaction and stability and is associated with gigantism
  88. PRKAR1A mutation causing pituitary-dependent Cushing disease in a patient with Carney complex
  89. Cabergoline-related impulse control disorder in an adolescent with a giant prolactinoma
  90. A unique haplotype of RCCX copy number variation: from the clinics of congenital adrenal hyperplasia to evolutionary genetics
  91. Pituitary Carcinoma in a Patient with an SDHB Mutation
  92. From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal
  93. Sporadic pituitary adenomas: the role of germline mutations and recommendations for genetic screening
  94. Genetic Aspects of Pituitary Adenomas
  95. Renin-Angiotensin System Blockade Improves Cardiac Indices in Acromegaly Patients
  96. Social, educational and vocational outcomes in patients with childhood-onset and young-adult-onset growth hormone deficiency
  97. The genetic background of acromegaly
  98. Succinate Dehydrogenase B (SDHB)-Associated Bladder Paragangliomas
  99. Pachydermoperiostosis Masquerading as Acromegaly
  100. Metformin prevents metabolic side effects during systemic glucocorticoid treatment
  101. Diagnostic challenges and management of a patient with acromegaly due to ectopic growth hormone-releasing hormone secretion from a bronchial carcinoid tumour
  102. Echocardiographic improvements following transsphenoidal surgery for acromegaly
  103. Genetics of pituitary adenomas
  104. Systematic Investigation of Expression of G2/M Transition Genes Reveals CDC25 Alteration in Nonfunctioning Pituitary Adenomas
  105. Outcomes of annual surveillance imaging in an adult and paediatric cohort of succinate dehydrogenase B mutation carriers
  106. The clinical, pathological and molecular differences between sparsely and densely granulated somatotroph adenomas
  107. Glioma in an AIP mutation carrier patient
  108. Pseudoacromegaly - a differential diagnostic problem for acromegaly
  109. Olfactory neuroblastoma: a multi centre clinical and pathological review
  110. Metformin alters an anti-proliferative effect of Mitotane in a human adrenocortical cancer (H295R) cell line: preliminary results
  111. The role of the microenvironment in the invasive phenotype of familial pituitary tumours
  112. Polymorphism or mutation? - The role of the R304Q missense AIP mutation in the predisposition to pituitary adenoma
  113. ESR2 mutations in RET mutation-negative familial medullary thyroid carcinoma
  114. Novel Genetic Causes of Pituitary Adenomas
  115. Increased Population Risk ofAIP-Related Acromegaly and Gigantism in Ireland
  116. Gigantism: X-linked acrogigantism and GPR101 mutations
  117. Characterisation of myocardial structure and function in adult-onset growth hormone deficiency using cardiac magnetic resonance
  118. Rapid Proteasomal Degradation of Mutant Proteins Is the Primary Mechanism Leading to Tumorigenesis in Patients With MissenseAIPMutations
  119. Signaling network map of the aryl hydrocarbon receptor
  120. Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study
  121. AIP inactivation leads to pituitary enlargement in the Zebrafish embryo model
  122. The Drosophila AIP orthologue is essential for actin cytoskeleton stabilisation and cell adhesion
  123. cAMP-specific PDE4 phosphodiesterases and AIP in the pathogenesis of pituitary tumors
  124. SomaticGPR101Duplication Causing X-Linked Acrogigantism (XLAG)—Diagnosis and Management
  125. Pheochromocytoma Is Characterized by Catecholamine-Mediated Myocarditis, Focal and Diffuse Myocardial Fibrosis, and Myocardial Dysfunction
  126. AIP mutations in young patients with acromegaly and the Tampico Giant: the Mexican experience
  127. Clinicopathologic features of familial pituitary adenomas
  128. Cancerous leptomeningitis and familial congenital hypopituitarism
  129. AIP and the somatostatin signalling in pituitary tumours
  130. Can immediate postoperative random growth hormone levels predict long-term cure in patients with acromegaly?
  131. Endocrine Tumor Genetics: Challenging Issues
  132. Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity
  133. Diagnosis of Acromegaly
  134. Clinical Features of Acromegaly☆
  135. Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly
  136. Additive Anti-Tumor Effects of Lovastatin and Everolimus In Vitro through Simultaneous Inhibition of Signaling Pathways
  137. Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study
  138. Childhood somatotroph pituitary adenomas due to aryl hydrocarbon receptor interacting protein (AIP) gene mutations
  139. Pegvisomant treatment for X-linked acrogigantism syndrome
  140. Achieving a consensus on managing idiopathic thickening of the pituitary stalk through a national multidisciplinary forum, meeting virtually
  141. In vitroeffects of Imatinib on somatotrophinoma cell line
  142. Silencing of aryl hydrocarbon receptor protein (AIP) up-regulates the small Rho GTPase, CDC42
  143. Novel targeted treatment combinations for malignant neuroendocrine tumour olfactory neuroblastoma
  144. Potential molecular mechanism of AIP-mediated cellular invasion
  145. The effect of AIP on AHR transcriptional activity: implications forAIPmutations pathogenicity
  146. Investigation of the invasive phenotype of AIP-mutated pituitary adenomas
  147. The epidemiology of pituitary adenomas in Iceland, 1955–2012: a nationwide population-based study
  148. Histopathology and molecular characterisation of intrauterine-diagnosed congenital craniopharyngioma
  149. Landscape of Familial Isolated and Young-Onset Pituitary Adenomas: Prospective Diagnosis inAIPMutation Carriers
  150. The effects of chronic candesartan treatment on cardiac and hepatic adenosine monophosphate-activated protein kinase in rats submitted to surgical stress
  151. Prostatic hyperplasia in acromegaly
  152. Treatment-resistant pediatric giant prolactinoma and multiple endocrine neoplasia type 1
  153. The Gene of the Ubiquitin-Specific Protease 8 Is Frequently Mutated in Adenomas Causing Cushing's Disease
  154. 15 YEARS OF PARAGANGLIOMA: The association of pituitary adenomas and phaeochromocytomas or paragangliomas
  155. Metabolic comorbidities in Cushing's syndrome
  156. Ghrelin
  157. Studying Cat (Felis catus) Diabetes: Beware of the Acromegalic Imposter
  158. The ubiquitin-specific protease 8 gene is frequently mutated in adenomas causing Cushing's disease
  159. Pituitary apoplexy in GH-deficient adults treated with GH - a KIMS database retrospective study
  160. Safety and Efficacy of Oral Octreotide in Acromegaly: Results of a Multicenter Phase III Trial
  161. Excessive Growth Hormone Expression in Male GH Transgenic Mice Adversely Alters Bone Architecture and Mechanical Strength
  162. Kallmann syndrome patient with gender dysphoria, multiple sclerosis, and thrombophilia
  163. Heterogeneous Genetic Background of the Association of Pheochromocytoma/Paraganglioma and Pituitary Adenoma: Results From a Large Patient Cohort
  164. Regulation of Aryl Hydrocarbon Receptor Interacting Protein (AIP) Protein Expression by MiR-34a in Sporadic Somatotropinomas
  165. Evaluation of genotype–phenotype relationships in patients referred for endocrine assessment in suspected Pendred syndrome
  166. Prostatic hyperplasia in acromegaly, a myth or reality: a case–control study
  167. GH deficiency after traumatic brain injury: improvement in quality of life with GH therapy: analysis of the KIMS database
  168. An unusual case of an ACTH-secreting macroadenoma with a germline variant in the aryl hydrocarbon receptor-interacting protein (AIP) gene
  169. Multi-parametric cardiovascular magnetic resonance imaging detects subclinical myocardial involvement in patients diagnosed with phaeochromocytoma
  170. A 25-Year-Old Woman with Headache and Joint Pain
  171. Clinical profile and outcome of patients with acromegaly according to the 2014 consensus guidelines: Impact of a multi-disciplinary team
  172. The role of ghrelin in weight-regulation disorders: Implications in clinical practice
  173. Sequence analysis of the catalytic subunit of PKA in somatotroph adenomas
  174. Low rate of germline AIP mutations in patients with apparently sporadic pituitary adenomas before the age of 40: a single-centre adult cohort
  175. Adrenal cancer in neurofibromatosis type 1: case report and DNA analysis
  176. Paediatric pituitary adenomas: rare, complex, and by no means benign
  177. Common Genetic Variants of the Human Steroid 21-Hydroxylase Gene (CYP21A2) Are Related to Differences in Circulating Hormone Levels
  178. Combination of 13-CisRetinoic Acid and Lovastatin: Marked Antitumor Potential In Vivo in a Pheochromocytoma Allograft Model in Female Athymic Nude Mice
  179. Effects of Long-term Growth Hormone Replacement in Adults With Growth Hormone Deficiency Following Cure of Acromegaly: A KIMS Analysis
  180. 122 Cardiac Abnormalities are Common in Patients Diagnosed with Phaeochromocytoma as Detected by Cardiovascular Magnetic Resonance Imaging
  181. Pituitary blastoma: a pathognomonic feature of germ-line DICER1 mutations
  182. Human AIP gene rescue lethality in a Drosophila melanogaster knockout model of AIP orthologue
  183. The anti-proliferative effect of anti-EGFR tyrosine kinase inhibitor in combination with mitotane on H295R adrenocortical cancer cells
  184. Clinical Experience in the Screening and Management of a Large Kindred With Familial Isolated Pituitary Adenoma Due to an Aryl Hydrocarbon Receptor Interacting Protein (AIP) Mutation
  185. Analysis of the AIP gene promoter
  186. Kallmann syndrome, gender dysphoria, thrombophilia and multiple sclerosis: a complex case report
  187. High incidence of cardiac involvement in patients diagnosed with phaeochromocytoma: a clinical study using cardiovascular magnetic resonance imaging
  188. RET mutation negative familial medullary thyroid carcinoma: four families and literature review
  189. Pre-clinical assessment of the impact of Erlotinib on adrenocortical cancer cells proliferation
  190. Epidemiology and etiopathogenesis of pituitary adenomas
  191. Metformin—mode of action and clinical implications for diabetes and cancer
  192. Preface
  193. Familial pituitary tumors
  194. Characterization of SNARE Proteins in Human Pituitary Adenomas: Targeted Secretion Inhibitors as a New Strategy for the Treatment of Acromegaly?
  195. MicroRNAs: Suggested role in pituitary adenoma pathogenesis
  196. Effects of smoking cessation on  -cell function, insulin sensitivity, body weight, and appetite
  197. The CB1 receptor mediates the peripheral effects of ghrelin on AMPK activity but not on growth hormone release
  198. CB1 receptor mediates the effects of glucocorticoids on AMPK activity in the hypothalamus
  199. A Comprehensive Next Generation Sequencing–Based Genetic Testing Strategy To Improve Diagnosis of Inherited Pheochromocytoma and Paraganglioma
  200. Fasting and postprandial liver glycogen content in patients with type 1 diabetes mellitus after successful pancreas-kidney transplantation with systemic venous insulin delivery
  201. Novel pathway for somatostatin analogs in patients with acromegaly
  202. GH excess in bGH transgenic mice adversely affects bone density, architecture and quality
  203. AIP (aryl hydrocarbon receptor interacting protein)
  204. Gene expression profiling of familial and sporadic pituitary adenomas
  205. Genetic and clinical characteristics of Serbian FIPA families
  206. Drosophila melanogasteras a model organism to study aryl hydrocarbon receptor interacting protein gene function
  207. A Novel Mutation in the Upstream Open Reading Frame of the CDKN1B Gene Causes a MEN4 Phenotype
  208. Familial Pituitary Adenomas
  209. Genes and giants
  210. De Novo HNF1b mutation as a cause for chronic treatment-resistant hypomagnesaemia
  211. Excessive GH expression in bGH transgenic mice adversely alters bone architecture and quality
  212. The role of microRNA miR-34a in the regulation of aryl hydrocarbon receptor interacting protein
  213. Invasion signature' revealed by the analysis of AIP positive and AIP mutation negative human pituitary adenomas
  214. Creation of a locus-specific database for AIP mutations
  215. Genetics of the Ghrelin System
  216. Genetics of Pituitary Adenomas
  217. Ghrelin and cannabinoids require the ghrelin receptor to affect cellular energy metabolism
  218. Structure of the TPR Domain of AIP: Lack of Client Protein Interaction with the C-Terminal α-7 Helix of the TPR Domain of AIP Is Sufficient for Pituitary Adenoma Predisposition
  219. Familial isolated pituitary adenomas: An emerging clinical entity
  220. ACTH-secreting Crooke cell carcinoma of the pituitary
  221. Genetic studies in a coexistence of acromegaly, pheochromocytoma, gastrointestinal stromal tumor (GIST) and thyroid follicular adenoma
  222. 2.7 Expression of a subset of microRNAs in clinically non-functioning pituitary adenomas correlates with tumor size
  223. Familial pituitary adenomas – who should be tested for AIP mutations?
  224. Somatostatin Analogs Modulate AIP in Somatotroph Adenomas: The Role of the ZAC1 Pathway
  225. MicroRNA miR-107 is overexpressed in pituitary adenomas and inhibits the expression of aryl hydrocarbon receptor-interacting protein in vitro
  226. Oncogene-induced senescence in pituitary adenomas and carcinomas
  227. Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines
  228. Mice lacking AMP-activated protein kinase  1 catalytic subunit have increased bone remodelling and modified skeletal responses to hormonal challenges induced by ovariectomy and intermittent PTH treatment
  229. Expression of guanylyl cyclase-B (GC-B/NPR2) receptors in normal human fetal pituitaries and human pituitary adenomas implicates a role for C-type natriuretic peptide
  230. Prostaglandin transporter mutations cause pachydermoperiostosis with myelofibrosis
  231. Genetic analysis in a patient presenting with meningioma and familial isolated pituitary adenoma (FIPA) reveals selective involvement of the R81X mutation of the AIP gene in the pathogenesis of the pituitary tumor
  232. Modifications in basal and stress-induced hypothalamic AMP-activated protein kinase (AMPK) activity in rats chronically treated with an angiotensin II receptor blocker
  233. Ghrelin Regulation of AMPK in the Hypothalamus and Peripheral Tissues
  234. Measurement of AMP-Activated Protein Kinase Activity and Expression in Response to Ghrelin
  235. Cardiovascular changes in patients with adult-onset growth hormone deficiency assessed by CMR
  236. Cardiovascular changes in patients with acromegaly assessed by CMR
  237. Genetic studies on the ghrelin, growth hormone secretagogue receptor (GHSR) and ghrelin O-acyl transferase (GOAT) genes
  238. The Immunophilin-Like Protein XAP2 Is a Negative Regulator of Estrogen Signaling through Interaction with Estrogen Receptor α
  239. Ghrelin in obesity and endocrine diseases
  240. miR-107 Is Overexpressed in Pituitary Adenomas and Inhibits the Expression of Aryl Hydrocarbon Receptor-Interacting Protein (AIP)
  241. Familial isolated pituitary adenoma syndrome
  242. Specific electrocardiographic features associated with Cushing’s disease
  243. AIP and its interacting partners
  244. WITHDRAWN: Ghrelin in obesity and endocrine diseases
  245. The ghrelin/GOAT/GHS-R system and energy metabolism
  246. AIPMutation in Pituitary Adenomas in the 18th Century and Today
  247. 2.3.11 Acromegaly
  248. The expression of ghrelin O-acyltransferase (GOAT) in human tissues
  249. Mechanisms of metformin action on glucose transport and metabolism in human adipocytes
  250. MicroRNA profile indicates downregulation of the TGFβ pathway in sporadic non-functioning pituitary adenomas
  251. Familial isolated pituitary adenomas experience at a single center: clinical importance of AIP mutation screening
  252. Down-Regulation of Wee1 Kinase by a Specific Subset of microRNA in Human Sporadic Pituitary Adenomas
  253. AIP gene and familial isolated pituitary adenomas
  254. Cyclins and their related proteins in pituitary tumourigenesis
  255. Role of the aryl hydrocarbon receptor-interacting protein in familial isolated pituitary adenoma
  256. Down-Regulation of Wee1 Kinase by a Specific Subset of microRNAs in Human Sporadic Pituitary Adenomas
  257. Alterations in Adipose Tissue during Critical Illness
  258. Treatment of acromegaly
  259. AMP-activated protein kinase (AMPK) activation regulates in vitro bone formation and bone mass
  260. Clinical, genetic and molecular characterization of patients with familial isolated pituitary adenomas (FIPA)
  261. AMP-activated protein kinase (AMPK) regulates in vitro bone formation and bone mass in vivo
  262. MicroRNA expression in ACTH-producing pituitary tumors: up-regulation of microRNA-122 and -493 in pituitary carcinomas
  263. Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families
  264. Ghrelin’s Role as a Major Regulator of Appetite and Its Other Functions in Neuroendocrinology
  265. Molecular Genetics of the Aip Gene in Familial Pituitary Tumorigenesis
  266. PL10 The curious case of ghrelin
  267. Analysis of IMP3 Expression in Normal and Neoplastic Human Pituitary Tissues
  268. Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists
  269. AMPK as a mediator of hormonal signalling
  270. Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors
  271. The role of ghrelin and ghrelin-receptor gene variants and promoter activity in type 2 diabetes
  272. Recent Clinical and Pathophysiological Advances in Non-Functioning Pituitary Adenomas
  273. Association Studies onGhrelinandGhrelin ReceptorGene Polymorphisms With Obesity
  274. Shedding light on the intricate puzzle of ghrelin's effects on appetite regulation
  275. AIP, a Protein Mutated in Familial Acromegaly, Plays a Role in the Regulation of Cell Proliferation and Shows Cell-Type Specific Subcellular Localisation
  276. Assessment of p27 (cyclin‐dependent kinase inhibitor 1B) and aryl hydrocarbon receptor‐interacting protein (AIP) genes in multiple endocrine neoplasia (MEN1) syndrome patients without any detectable MEN1 gene mutations
  277. Familial Isolated Pituitary Adenomas
  278. Familial Isolated Pituitary Adenomas
  279. A Genetic Study of the Ghrelin and Growth Hormone Secretagogue Receptor (GHSR) Genes and Stature
  280. STOP AKTING TO TREAT ENDOCRINE TUMOURS
  281. The Yin and Yang of the Ghrelin Gene Products
  282. The potential role of D2 dopamine receptors as a target in the management of neuroendocrine tumors
  283. Changes in Adenosine 5′-Monophosphate-Activated Protein Kinase as a Mechanism of Visceral Obesity in Cushing’s Syndrome
  284. Ghrelin Receptor Gene Polymorphisms and Body Size in Children and Adults
  285. Protein western array analysis in human pituitary tumours: insights and limitations
  286. The Role of the Aryl Hydrocarbon Receptor-Interacting Protein Gene in Familial and Sporadic Pituitary Adenomas
  287. AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome
  288. Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms
  289. The role of somatostatin analogues in the treatment of neuroendocrine tumours
  290. HLA-DQ3 is a probable risk factor for CMV infection in high-risk kidney transplant patients
  291. The Orexigenic Effect of Ghrelin Is Mediated through Central Activation of the Endogenous Cannabinoid System
  292. The Role of AMP-Activated Protein Kinase in Obesity
  293. Octreotide and the mTOR Inhibitor RAD001 (Everolimus) Block Proliferation and Interact with the Akt-mTOR-p70S6K Pathway in a Neuro-Endocrine Tumour Cell Line
  294. Contents / Foreword / Preface
  295. A new variation in the promoter region, the −604 C>T, and the Leu72Met polymorphism of the ghrelin gene are associated with protection to insulin resistance
  296. Metabolic and hormonal changes during the refeeding period of prolonged fasting
  297. Examining the Candidacy of Ghrelin as a Gene Responsible for Variation in Adult Stature in a United Kingdom Population with Type 2 Diabetes
  298. Ghrelin in neuroendocrine organs and tumours
  299. A mutation and expression analysis of the oncogene BRAF in pituitary adenomas
  300. Ghrelin, the peripheral hunger hormone
  301. Appetite and Metabolic Effects of Ghrelin and Cannabinoids: Involvement of AMP-Activated Protein Kinase
  302. The Farnesoid X Receptor Is Expressed in Breast Cancer and Regulates Apoptosis and Aromatase Expression
  303. PPAR-? expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-? receptor
  304. Macro- and micronutrient losses and nutritional status resulting from 44 days of total fasting in a non-obese man
  305. Effect of Gastric Bypass and Gastric Banding on Proneurotensin Levels in Morbidly Obese Patients
  306. Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours
  307. Expanding role of AMPK in endocrinology
  308. Ghrelin and cardiovascular health
  309. Refeeding David Blaine — Studies after a 44-Day Fast
  310. Differential gene expression in pituitary adenomas by oligonucleotide array analysis
  311. Enhanced protein kinase B/Akt signalling in pituitary tumours
  312. Fasting and Postprandial Hyperghrelinemia in Prader-Willi Syndrome Is Partially Explained by Hypoinsulinemia, and Is Not Due to Peptide YY3–36Deficiency or Seen in Hypothalamic Obesity Due to Craniopharyngioma
  313. Cannabinoids and Ghrelin Have Both Central and Peripheral Metabolic and Cardiac Effects via AMP-activated Protein Kinase
  314. A HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas
  315. Striant™ SR: a novel, effective and convenient testosterone therapy for male hypogonadism
  316. Akting and Cycling: A Tale of the Pituitary
  317. Theobromine inhibits sensory nerve activation and cough
  318. The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin
  319. Ghrelin: update on a novel hormonal system
  320. Ghrelin exerts a proliferative effect on a rat pituitary somatotroph cell line via the mitogen-activated protein kinase pathway
  321. A Comparison of a Novel Testosterone Bioadhesive Buccal System, Striant, with a Testosterone Adhesive Patch in Hypogonadal Males
  322. Ghrelin?a hormone with multiple functions
  323. Elevated Fasting Plasma Ghrelin in Prader-Willi Syndrome Adults Is Not Solely Explained by Their Reduced Visceral Adiposity and Insulin Resistance
  324. Non-Growth Hormone Endocrine Actions of Ghrelin
  325. Identification of Adrenocorticotropin Receptor Messenger Ribonucleic Acid in the Human Pituitary and Its Loss of Expression in Pituitary Adenomas
  326. The Kruppel-like transcription factor 6 gene in sporadic pituitary tumours
  327. Reduced expression of the growth hormone and type 1 insulin‐like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor
  328. Rapid desensitisation of the GH secretagogue (ghrelin) receptor to hexarelin in vitro
  329. Activating point mutations in cyclin-dependent kinase 4 are not seen in sporadic pituitary adenomas, insulinomas or Leydig cell tumours
  330. Ghrelin is Released from Rat Hypothalamic Explants and Stimulates Corticotrophin-releasing Hormone and Arginine-vasopressin
  331. Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency
  332. Macrophage migration inhibitory factor expression is increased in pituitary adenoma cell nuclei
  333. Sequence analysis of the PRKAR1A gene in sporadic somatotroph and other pituitary tumours
  334. A Variation in the Ghrelin Gene Increases Weight and Decreases Insulin Secretion in Tall, Obese Children
  335. A Variation in the Ghrelin Gene Increases Weight and Decreases Insulin Secretion in Tall, Obese Children
  336. Cell Cycle Dysregulation in Human Pituitary Tumours
  337. The Tissue Distribution of the mRNA of Ghrelin and Subtypes of Its Receptor, GHS-R, in Humans
  338. Expression of Phosphorylated p27Kip1Protein and Jun Activation Domain-Binding Protein 1 in Human Pituitary Tumors
  339. Expression of Phosphorylated p27Kip1 Protein and Jun Activation Domain-Binding Protein 1 in Human Pituitary Tumors
  340. The Tissue Distribution of the mRNA of Ghrelin and Subtypes of Its Receptor, GHS-R, in Humans
  341. Optimal Response Criteria for the Human CRH Test in the Differential Diagnosis of ACTH-Dependent Cushing's Syndrome
  342. Response of Serum Macrophage Migration Inhibitory Factor Levels to Stimulation or Suppression of the Hypothalamo-Pituitary-Adrenal Axis in Normal Subjects and Patients with Cushing's Disease
  343. The Effect of Growth Hormone Secretagogues and Neuropeptide Y on Hypothalamic Hormone Release from Acute Rat Hypothalamic Explants
  344. The release of leptin and its effect on hormone release from human pituitary adenomas
  345. Expression of 11β-Hydroxysteroid Dehydrogenase Isoenzymes in the Human Pituitary: Induction of the Type 2 Enzyme in Corticotropinomas and Other Pituitary Tumors
  346. Ghrelin, the endogenous ligand to the growth hormone secretagogue receptor — expression in human hypothalamus and pituitary
  347. Expression of 11 -Hydroxysteroid Dehydrogenase Isoenzymes in the Human Pituitary: Induction of the Type 2 Enzyme in Corticotropinomas and Other Pituitary Tumors
  348. Imprinting of the Gsα gene GNAS1 in the pathogenesis of acromegaly
  349. The Expression of the Growth Hormone Secretagogue Receptor Ligand Ghrelin in Normal and Abnormal Human Pituitary and Other Neuroendocrine Tumors1
  350. Comparison of Somatostatin Analog and Meta-Iodobenzylguanidine Radionuclides in the Diagnosis and Localization of Advanced Neuroendocrine Tumors
  351. The Expression of the Growth Hormone Secretagogue Receptor Ligand Ghrelin in Normal and Abnormal Human Pituitary and Other Neuroendocrine Tumors
  352. Presence of Ghrelin in Normal and Adenomatous Human Pituitary
  353. How common are polycystic ovaries and the polycystic ovarian syndrome in women with Cushing's syndrome?
  354. Expression of the Pituitary Transcription Factor Ptx-1, But Not That of theTrans-Activating Factor Prop-1, Is Reduced in Human Corticotroph Adenomas and Is Associated with Decreasedα -Subunit Secretion1
  355. Expression of the Pituitary Transcription Factor Ptx-1, But Not That of the Trans-Activating Factor Prop-1, Is Reduced in Human Corticotroph Adenomas and Is Associated with Decreased  -Subunit Secretion
  356. Low Expression of the Cell Cycle Inhibitor p27Kip1in Normal Corticotroph Cells, Corticotroph Tumors, and Malignant Pituitary Tumors
  357. Hexarelin as a test of pituitary reserve in patients with pituitary disease
  358. The Growth Hormone Secretagogue Hexarelin Stimulates the Hypothalamo-Pituitary-Adrenal Axis via Arginine Vasopressin
  359. The growth hormone secretagogue receptor
  360. Expression of menin gene mRNA in pituitary tumours
  361. The Effects of GH-Secretagogues on Human Pituitary Cells in Culture and on Rat Hypothalamic Tissue
  362. Leptin and the thyroid — A puzzle with missing pieces
  363. Expression of the Growth Hormone Secretagogue Receptor in Pituitary Adenomas and Other Neuroendocrine Tumors1
  364. Expression of the Growth Hormone Secretagogue Receptor in Pituitary Adenomas and Other Neuroendocrine Tumors
  365. The Pathophysiology of Circulating Corticotropin-Releasing Hormone-Binding Protein Levels in the Human
  366. Leptin levels do not change acutely with food administration in normal or obese subjects, but are negatively correlated with pituitary‐adrenal activity
  367. Differential stimulation of corticol and dehydropiandrosterone levels by food in obese and normal subjects: relation to body fat distribution
  368. Intérêt clinique des neuropeptides GHRH et GHRP
  369. Diagnosis of Growth Hormone Deficiency in Adults
  370. The effect of an opiate antagonist on the hormonal changes induced by hexarelin
  371. Growth hormone-releasing peptide and its analogues
  372. Determination of Direct Effects of Cytokines on Release of Neuropeptides from Rat Hypothalamus by an in Vitro Method